Preclinical models in ovarian cancer

Danielle E. Bolland, Karen McLean

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The overall poor clinical outcome for women with ovarian cancer necessitates accurate tumor model systems that can yield preclinical advances for translation to new patient-centered treatment strategies. Our preclinical knowledge of ovarian cancer is largely based on traditional in vitro two-dimensional cell culture studies; however, this approach fails to fully recapitulate the complexity of the tumor. Multiple newer model systems have been established, including three-dimensional cell culture models, genetically engineered mouse models, and patient-derived xenografts. These models seek to address the important concepts of the tumor microenvironment and tumor heterogeneity. Genetically engineered mouse models additionally provide the opportunity to study the genetic underpinnings of tumor development as well as carry out cancer prevention studies. In this chapter, we will discuss the application of each of these three model systems to the study of ovarian cancer and drug development, including the unique strengths and limitations of each approach.

Original languageEnglish (US)
Title of host publicationAnimal Models in Cancer Drug Discovery
PublisherElsevier
Pages31-57
Number of pages27
ISBN (Electronic)9780128147054
ISBN (Print)9780128147047
DOIs
StatePublished - Apr 17 2019
Externally publishedYes

Keywords

  • Chemoresitance
  • Genetically modified mouse models
  • Ovarian cancer
  • Patient-derived xenografts
  • Tumor spheroids

Fingerprint Dive into the research topics of 'Preclinical models in ovarian cancer'. Together they form a unique fingerprint.

Cite this